Safety of Serial Monthly Administration of Triple‐Dose Gadopentetate Dimeglumine in Multiple Sclerosis Patients: Preliminary Results of the BECOME Trial

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Neuroimaging

• Publication date

  2005-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1552-6569.2005.tb00326.xPMID 15951416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.

  1998cited by this paper
• Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging.

  1998cited by this paper
• Triple‐Dose Versus Single‐Dose Gadoteridol in Multiple Sclerosis Patients

  1994cited by this paper
• Safety assessment of gadopentetate dimeglumine in U.S. clinical trials.

  1990cited by this paper

• Gray Matter Nucleus Hyperintensity After Monthly Triple-Dose Gadopentetate Dimeglumine With Long-term Magnetic Resonance Imaging

  2020cites this paper
• MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia.

  2020cites this paper
• Hypophosphatemia is Associated with the Serial Administration of Triple‐Dose Gadolinium to Patients for Brain MRI

  2015cites this paper
• Clinical consequences of MRI activity in treated multiple sclerosis

  2011cites this paper
• Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

  2009cites this paper
• New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

  2009cites this paper
• Effect of anti-IFNβ antibodies on MRI lesions of MS patients in the BECOME study

  2009cites this paper
• Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

  2009cites this paper
• Interferon-β1b for the treatment of multiple sclerosis

  2008cites this paper
• MRI in multiple sclerosis: What’s inside the toolbox?

  2007cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2006cites this paper